LB Pharmaceuticals Inc (LBRX)

Currency in USD
37.22
+2.61(+7.54%)
Closed·
37.220.00(0.00%)
·
LBRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
35.0138.50
52 wk Range
14.3250.16
Key Statistics
Prev. Close
37.22
Open
35.01
Day's Range
35.01-38.5
52 wk Range
14.32-50.16
Volume
642.58K
Average Volume (3m)
348.9K
1-Year Change
141.0622%
Book Value / Share
11.59
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LBRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
58.00
Upside
+55.83%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

LB Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 58.00
(+55.83% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord
Buy65.00+74.64%-New CoverageOct 09, 2026
Guggenheim
Buy80.00+114.94%-New CoverageOct 05, 2026
Roth/MKM
Hold---DowngradeOct 05, 2026
Needham
Buy68.00+82.70%-New CoverageOct 02, 2026
H.C. Wainwright
Buy60.00+61.20%45.00MaintainAug 24, 2026

Earnings

Latest Release
Aug 11, 2026
EPS / Forecast
-1,71 / -0,78
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LBRX Income Statement

Compare LBRX to Peers and Sector

Metrics to compare
LBRX
Peers
Sector
Relationship
P/E Ratio
−14.0x−4.0x−0.3x
PEG Ratio
−0.14−0.850.00
Price/Book
3.6x−13.3x2.6x
Price / LTM Sales
-2.4x3.0x
Upside (Analyst Target)
55.8%94.0%61.2%
Fair Value Upside
Unlock5.6%7.2%Unlock

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6,93M21,51%258,09M
Other Institutional Investors
35,37M78,49%1,32B
Public Companies & Retail Investors
0,000,00%0,00
Total
42,3M100,00%1,57B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Deep Track Capital, LP10,39%3 352 804124 791
BlackRock, Inc.8,48%2 734 305101 771

FAQ

What Is the LB Pharmaceuticals (LBRX) Stock Price Today?

The LB Pharmaceuticals stock price today is 37,22 USD.

What Stock Exchange Does LB Pharmaceuticals Trade On?

LB Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for LB Pharmaceuticals?

The stock symbol for LB Pharmaceuticals is "LBRX."

What Is the LB Pharmaceuticals Market Cap?

As of today, LB Pharmaceuticals market cap is 1,20B USD.

What Is LB Pharmaceuticals's Earnings Per Share (TTM)?

The LB Pharmaceuticals EPS (TTM) is -3,81.

When Is the Next LB Pharmaceuticals Earnings Date?

LB Pharmaceuticals will release its next earnings report on Nov 05, 2026.

From a Technical Analysis Perspective, Is LBRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has LB Pharmaceuticals Stock Split?

LB Pharmaceuticals has split 0 times.

How Many Employees Does LB Pharmaceuticals Have?

LB Pharmaceuticals has 49 employees.

What is the current trading status of LB Pharmaceuticals (LBRX)?

As of Oct 11, 2026, LB Pharmaceuticals (LBRX) is trading at a price of 37,22 USD, with a previous close of 37,22 USD. The stock has fluctuated within a day range of 35,01 USD to 38,50 USD, while its 52-week range spans from 14,32 USD to 50,16 USD.

What Is LB Pharmaceuticals (LBRX) Price Target According to Analysts?

The average 12-month price target for LB Pharmaceuticals is 58,00 USD, with a high estimate of 80 USD and a low estimate of 35 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +55,83% Upside potential.

What Is the LBRX Premarket Price?

LBRX's last pre-market stock price is 35,99 USD. The pre-market share volume is 90,00, and the stock has decreased by 1,38, or 3,99%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.